SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration.
Economic evaluations in wet age-related macular degeneration (ARMD) is hampered as often utility values for solely one eye are used, mostly the better-seeing eye (BSE). Moreover, frequently chosen methods rely on patient values and/or disease specific measures, while economic evaluations prefer gene...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5321468?pdf=render |
| _version_ | 1811321499719565312 |
|---|---|
| author | Martijn S Visser Sankha Amarakoon Tom Missotten Reinier Timman Jan J Busschbach |
| author_facet | Martijn S Visser Sankha Amarakoon Tom Missotten Reinier Timman Jan J Busschbach |
| author_sort | Martijn S Visser |
| collection | DOAJ |
| description | Economic evaluations in wet age-related macular degeneration (ARMD) is hampered as often utility values for solely one eye are used, mostly the better-seeing eye (BSE). Moreover, frequently chosen methods rely on patient values and/or disease specific measures, while economic evaluations prefer generic quality of life (QoL) measures based on societal preferences. The generic QoL utility instrument EQ-5D has shown to be insensitive for differences in visual acuity. The aim of this study was therefore to provide societal utility values, using the generic SF-6D, for health states acknowledging both BSE and worse-seeing eye (WSE).SF-6D utility values of 191 ARMD patients (≥65 years) with 153 follow-up measures at 1 year were used to fill health states defined by the combination of BSE and WSE using Snellen equivalents; no visual loss (≥20/40), mild-moderate (<20/40->20/200) and severe (≤20/200).QoL utilities were estimated for the SF-6D, ranging from 0.740 for ARMD patients without visual loss to 0.684 for patients with a combination of mild-moderate visual loss in their BSE and severe visual loss in their WSE.Societal utility values are provided for ARMD patients using the generic QoL instrument SF-6D for visual acuity health states based on both BSE and WSE. The range of the values is smaller than previous elicited utilities with the disease-specific VisQoL. Besides, the utility values are placed on a more realistic position on the utility scale, and SF-6D utility values avoid the problem associated with the interpretation of disease-specific utility values. |
| first_indexed | 2024-04-13T13:18:51Z |
| format | Article |
| id | doaj.art-e1799213d9224e4ca0effb902b96b393 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T13:18:51Z |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-e1799213d9224e4ca0effb902b96b3932022-12-22T02:45:23ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01122e016981610.1371/journal.pone.0169816SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration.Martijn S VisserSankha AmarakoonTom MissottenReinier TimmanJan J BusschbachEconomic evaluations in wet age-related macular degeneration (ARMD) is hampered as often utility values for solely one eye are used, mostly the better-seeing eye (BSE). Moreover, frequently chosen methods rely on patient values and/or disease specific measures, while economic evaluations prefer generic quality of life (QoL) measures based on societal preferences. The generic QoL utility instrument EQ-5D has shown to be insensitive for differences in visual acuity. The aim of this study was therefore to provide societal utility values, using the generic SF-6D, for health states acknowledging both BSE and worse-seeing eye (WSE).SF-6D utility values of 191 ARMD patients (≥65 years) with 153 follow-up measures at 1 year were used to fill health states defined by the combination of BSE and WSE using Snellen equivalents; no visual loss (≥20/40), mild-moderate (<20/40->20/200) and severe (≤20/200).QoL utilities were estimated for the SF-6D, ranging from 0.740 for ARMD patients without visual loss to 0.684 for patients with a combination of mild-moderate visual loss in their BSE and severe visual loss in their WSE.Societal utility values are provided for ARMD patients using the generic QoL instrument SF-6D for visual acuity health states based on both BSE and WSE. The range of the values is smaller than previous elicited utilities with the disease-specific VisQoL. Besides, the utility values are placed on a more realistic position on the utility scale, and SF-6D utility values avoid the problem associated with the interpretation of disease-specific utility values.http://europepmc.org/articles/PMC5321468?pdf=render |
| spellingShingle | Martijn S Visser Sankha Amarakoon Tom Missotten Reinier Timman Jan J Busschbach SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration. PLoS ONE |
| title | SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration. |
| title_full | SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration. |
| title_fullStr | SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration. |
| title_full_unstemmed | SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration. |
| title_short | SF-6D utility values for the better- and worse-seeing eye for health states based on the Snellen equivalent in patients with age-related macular degeneration. |
| title_sort | sf 6d utility values for the better and worse seeing eye for health states based on the snellen equivalent in patients with age related macular degeneration |
| url | http://europepmc.org/articles/PMC5321468?pdf=render |
| work_keys_str_mv | AT martijnsvisser sf6dutilityvaluesforthebetterandworseseeingeyeforhealthstatesbasedonthesnellenequivalentinpatientswithagerelatedmaculardegeneration AT sankhaamarakoon sf6dutilityvaluesforthebetterandworseseeingeyeforhealthstatesbasedonthesnellenequivalentinpatientswithagerelatedmaculardegeneration AT tommissotten sf6dutilityvaluesforthebetterandworseseeingeyeforhealthstatesbasedonthesnellenequivalentinpatientswithagerelatedmaculardegeneration AT reiniertimman sf6dutilityvaluesforthebetterandworseseeingeyeforhealthstatesbasedonthesnellenequivalentinpatientswithagerelatedmaculardegeneration AT janjbusschbach sf6dutilityvaluesforthebetterandworseseeingeyeforhealthstatesbasedonthesnellenequivalentinpatientswithagerelatedmaculardegeneration |